Compare RPD & ACHV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RPD | ACHV |
|---|---|---|
| Founded | 2000 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 746.5M | 618.0M |
| IPO Year | 2015 | 2018 |
| Metric | RPD | ACHV |
|---|---|---|
| Price | $11.81 | $7.99 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 23 | 3 |
| Target Price | ★ $15.05 | $14.67 |
| AVG Volume (30 Days) | ★ 2.3M | 1.3M |
| Earning Date | 05-05-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.11 | N/A |
| Revenue | ★ $685,083,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $0.54 | N/A |
| P/E Ratio | $107.68 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.97 | $2.62 |
| 52 Week High | $21.26 | $8.61 |
| Indicator | RPD | ACHV |
|---|---|---|
| Relative Strength Index (RSI) | 53.30 | 69.43 |
| Support Level | $5.86 | $4.09 |
| Resistance Level | $14.27 | N/A |
| Average True Range (ATR) | 0.96 | 0.38 |
| MACD | -0.06 | 0.13 |
| Stochastic Oscillator | 35.79 | 75.00 |
Founded in 2000, Rapid7 is a cybersecurity company that began providing vulnerability management solutions. It has, however, expanded its portfolio to provide extended detection and response; security information and event management; cloud security, threat intelligence, and application security; and security orchestration, automation, and response. The Boston-based company went public in 2015.
Achieve Life Sciences Inc is a late-stage clinical specialty pharmaceutical company with the sole mission to address the nicotine dependence epidemic through the development and commercialization of cytisinicline. Cytisinicline, is a naturally occurring alkaloid. Additionally, The company has completed a Phase 2 study with cytisinicline in vaping cessation and conducted a successful end-of-Phase 2 meeting with the FDA for a future vaping indication. It operates in one operating segment, development and commercialization of cytisinicline for nicotine dependence, with operations located in Canada, the United States and the U.K.